ERSAP Preceptorship Program

Preceptorships

Testimonials

Dr. Fatou S.D. Sene (Senegal) at University of Bordeaux in 2011

From 1-15 September 2011, I completed a training activity through the iCMLf and its partner, the Max Foundation. The training included the sponsorship of a patient assistance program, giving free a...

This program is designed for clinicians from Emerging Economic Regions with a specific interest in the treatment of CML and a significant CML patient load. The program enhances clinical knowledge and skills in the treatment of CML through preceptorships at internationally renowned CML centres.

Participants are part of the clinical team at the host site for the duration of the preceptorship, undertaking seminars and laboratory work where appropriate. Through this practical application of learning, clinicians attending the preceptorship have the opportunity to develop and enhance clinical knowledge to take back and share with colleagues in their country of origin. The programs are 'no profit' for the specialist CML centres, which donate their staff and resources to facilitate the program.

About to start its third year, the ERSAP Preceptorship Program is having a positive impact in the treatment of CML across emerging economic regions. The map below illustrates that preceptors have originated from a wide variety of countries in every potential emerging region.

You need to upgrade your Flash Player

Feedback from preceptors has confirmed that the goals of the program are being met, indicating improved knowledge and plans to share this with colleagues at home. Preceptors form collaborations with the host centre and many are undertaking further research projects. The following comments are examples of this feedback:

"It was an honor and a pleasure to have participated in this training, despite the vast difference between these institutions and hospitals in developing countries. It is certain that all is not feasible to us but we can certainly learn to improve our management." -- TH Madagascar

"…it was very useful to learn both the clinical and laboratory aspects of Quantitative BCR ABL and I think this will certainly improve the management of our patients." -- RS Pakistan

"…I have clarity in my mind on how to proceed with management of patients who become resistant to first line tyrosine kinase inhibitors and even those who are resistant to second-line TKIs." -- PM India

We are delighted to announce that the ERSAP Preceptorship Program will continue in 2012 and we still have many countries to reach so please share the information about the ERSAP Preceptorship Program with colleagues who may benefit. Applications for the 2012 program are now closed. Expressions of interest for the 2013 program can be sent to This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Last Updated on Wednesday, 21 December 2011 22:56 |

Selection Criteria & Application Process for Participants

The iCMLf seeks to improve the resources and knowledge of physicians treating patients with CML in emerging regions. The iCMLf will select up to 30 haematologists for the program whose attendance is expected to provide most benefit in this CML community. Candidates should have a special interest in CML management and be able to demonstrate their ability to apply and disseminate to colleagues knowledge gained from the program.

Apply now to participate in the ERSAP Preceptorship program 2012

The iCMLf is pleased to announce that the Emerging Regions Support and Partnership (ERSAP) Preceptorship Program is now seeking applications for 2012. The intention is to enhance the knowledge of physicians treating CML patients in emerging regions. Preceptorships will take place at 10 international specialist CML centres and last for 3-4 weeks. Applications close on the 16 Dec 2011. More information here.

Last Updated on Saturday, 05 November 2011 23:36 |

Preceptorship Program Content

Through one-on-one tuition and hands-on experience, participants will conclude the program with a practical understanding of the latest information influencing the care of patients with CML. This will include:
• therapies to treat CML; efficacy, toxicity and the management of side effects
• monitoring guidelines
• management of resistance
• role of allograft in CML
• developments in novel therapies, vaccines and drug cessation

The preceptorships are designed as an interactive process with participants steering their own education throughout the program.

Last Updated on Monday, 18 October 2010 08:17 |

Participating Centers of the 2012 Preceptorship Program

Preceptorships will take place at ten designated international specialist CML centres and last for 3-4 weeks. Find detailed descriptions of the participating centers here.

Please donate

Testimonials